However, more data on the relationship of KIT overexpression and response to TKI in the setting of wild type KIT should be collected to assess whether the amount of wild type KIT transcript in a tumor could be utilized to predict the patient’s response to imatinib and other TKIs. The gene discussed is KIT; the disease is neoplasm.